<?xml version="1.0" encoding="UTF-8"?>
<p>Neonatal and pediatric LRTIs and RSV are often mild, but can be associated with significant health resource utilization and result in an important burden on the patients, families, infrastructure, and budget of public healthcare systems [
 <xref ref-type="bibr" rid="B1">1</xref>]. Economic analyses indicate that substantial costs are associated with outpatient physician office and emergency department visits, but that a majority of the financial burden is accounted for by costs in inpatient hospital settings [
 <xref ref-type="bibr" rid="B2">2</xref>,
 <xref ref-type="bibr" rid="B3">3</xref>]. LRTI and RSV/LRTI hospitalization rates for all children &lt;2 years of age vary between 0.5% and 2% [
 <xref ref-type="bibr" rid="B4">4</xref>]. In comparison, LRTI, and particularly RSV specific LRTI, hospitalization rates and lengths of stay in infants and high-risk infants are substantially increased and associated with additional costs [
 <xref ref-type="bibr" rid="B3">3</xref>,
 <xref ref-type="bibr" rid="B4">4</xref>]. High-risk infants include early and late-preterm infants and those with bronchopulmonary dysplasia and congenital heart disease [
 <xref ref-type="bibr" rid="B3">3</xref>,
 <xref ref-type="bibr" rid="B5">5</xref>].
</p>
